CD8+ T cells prevent antigen-induced antibody-dependent enhancement of dengue disease in mice

Journal of Immunology

Volumn 193, Issue 8, 2014, Pages 4117-4124

  Zellweger, Raphaël M ^a   Eddy, William E ^a   Tang, William W ^a   Miller, Robyn ^a   Shresta, Sujan ^a  

^a LA JOLLA INSTITUTE FOR ALLERGY AND IMMUNOLOGY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALUMINUM HYDROXIDE; ANTIBODY; ANTIGEN; IMMUNOGLOBULIN G; IMMUNOLOGICAL ADJUVANT; VIRUS ANTIBODY; VIRUS ANTIGEN;

ADOPTIVE TRANSFER; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CD8+ T LYMPHOCYTE; CELL ISOLATION; CONTROLLED STUDY; DENGUE; DENGUE VIRUS; DISEASE SEVERITY; ENZYME LINKED IMMUNOSORBENT ASSAY; IN VIVO STUDY; MOUSE; NONHUMAN; OUTCOME ASSESSMENT; ULTRAVIOLET RADIATION; VIRUS LOAD; WILD TYPE; ANIMAL; ANTIBODY DEPENDENT ENHANCEMENT; IMMUNOLOGY; PASSIVE IMMUNIZATION; TRANSGENIC MOUSE; TRANSPLANTATION;

ADJUVANTS, IMMUNOLOGIC; ADOPTIVE TRANSFER; ANIMALS; ANTIBODIES, VIRAL; ANTIBODY-DEPENDENT ENHANCEMENT; ANTIGENS, VIRAL; CD8-POSITIVE T-LYMPHOCYTES; DENGUE; DENGUE VIRUS; IMMUNIZATION, PASSIVE; IMMUNOGLOBULIN G; MICE; MICE, TRANSGENIC; VIRAL LOAD;

EID: 84907487372     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1401597     Document Type: Article

References (52)

1. Guzman, M. G., M. Alvarez, and S. B. Halstead. 2013. Secondary infection as a risk factor for dengue hemorrhagic fever/dengue shock syndrome: an historical perspective and role of antibody-dependent enhancement of infection. Arch. Virol. 158: 1445-1459.
2. Carod-Artal, F. J., O. Wichmann, J. Farrar, and J. Gascón. 2013. Neurological complications of dengue virus infection. Lancet Neurol. 12: 906-919.
3. Halstead, S. B. 2007. Dengue. Lancet 370: 1644-1652.
4. World Health Organization. 2009. Dengue: Guidelines for Diagnosis, Treatment, Prevention and Control. World Health Organization, Geneva, Switzerland.
5. Bhatt, S., P. W. Gething, O. J. Brady, J. P. Messina, A. W. Farlow, C. L. Moyes, J. M. Drake, J. S. Brownstein, A. G. Hoen, O. Sankoh, et al. 2013. The global distribution and burden of dengue. Nature 496: 504-507.
6. Beatty, M. E., A. Stone, D.W. Fitzsimons, J. N. Hanna, S. K. Lam, S. Vong, M. G. Guzman, J. F. Mendez-Galvan, S. B. Halstead, G. W. Letson, et al; Asia-Pacific and Americas Dengue Prevention Boards Surveillance Working Group. 2010. Best practices in dengue surveillance: a report from the Asia-Pacific and Americas Dengue Prevention Boards. PLoS Negl. Trop. Dis. 4: e890.
7. Halstead, S. B. 1982. Immune enhancement of viral infection. Prog. Allergy 31: 301-364.
8. Halstead, S. B. 2003. Neutralization and antibody-dependent enhancement of dengue viruses. Adv. Virus Res. 60: 421-467.
9. Halstead, S. B., S. Nimmannitya, and S. N. Cohen. 1970. Observations related to pathogenesis of dengue hemorrhagic fever. IV. Relation of disease severity to antibody response and virus recovered. Yale J. Biol. Med. 42: 311-328.
10. Kliks, S. C., A. Nisalak, W. E. Brandt, L. Wahl, and D. S. Burke. 1989. Antibodydependent enhancement of dengue virus growth in human monocytes as a risk factor for dengue hemorrhagic fever. Am. J. Trop. Med. Hyg. 40: 444-451.
11. Boonnak, K., B. M. Slike, T. H. Burgess, R. M. Mason, S. J. Wu, P. Sun, K. Porter, I. F. Rudiman, D. Yuwono, P. Puthavathana, and M. A. Marovich. 2008. Role of dendritic cells in antibody-dependent enhancement of dengue virus infection. J. Virol. 82: 3939-3951.
12. Kou, Z., M. Quinn, H. Chen, W. W. Rodrigo, R. C. Rose, J. J. Schlesinger, and X. Jin. 2008. Monocytes, but not T or B cells, are the principal target cells for dengue virus (DV) infection among human peripheral blood mononuclear cells. J. Med. Virol. 80: 134-146.
13. Mehlhop, E., C. Ansarah-Sobrinho, S. Johnson, M. Engle, D. H. Fremont, T. C. Pierson, and M. S. Diamond. 2007. Complement protein C1q inhibits antibody-dependent enhancement of flavivirus infection in an IgG subclassspecific manner. Cell Host Microbe 2: 417-426.
14. Pierson, T. C., Q. Xu, S. Nelson, T. Oliphant, G. E. Nybakken, D. H. Fremont, and M. S. Diamond. 2007. The stoichiometry of antibody-mediated neutralization and enhancement of West Nile virus infection. Cell Host Microbe 1: 135-145.
15. Goncalvez, A. P., R. E. Engle, M. St Claire, R. H. Purcell, and C. J. Lai. 2007. Monoclonal antibody-mediated enhancement of dengue virus infection in vitro and in vivo and strategies for prevention. Proc. Natl. Acad. Sci. USA 104: 9422-9427.
16. Halstead, S. B. 1979. In vivo enhancement of dengue virus infection in rhesus monkeys by passively transferred antibody. J. Infect. Dis. 140: 527-533.
17. Balsitis, S. J., K. L. Williams, R. Lachica, D. Flores, J. L. Kyle, E. Mehlhop, S. Johnson, M. S. Diamond, P. R. Beatty, and E. Harris. 2010. Lethal antibody enhancement of dengue disease in mice is prevented by Fc modification. PLoS Pathog. 6: e1000790.
18. Zellweger, R. M., T. R. Prestwood, and S. Shresta. 2010. Enhanced infection of liver sinusoidal endothelial cells in a mouse model of antibody-induced severe dengue disease. Cell Host Microbe 7: 128-139.
19. Yauch, L. E., R. M. Zellweger, M. F. Kotturi, A. Qutubuddin, J. Sidney, B. Peters, T. R. Prestwood, A. Sette, and S. Shresta. 2009. A protective role for dengue virus-specific CD8+ T cells. J. Immunol. 182: 4865-4873.
20. Prestwood, T. R., D. M. Prigozhin, K. L. Sharar, R. M. Zellweger, and S. Shresta. 2008. A mouse-passaged dengue virus strain with reduced affinity for heparan sulfate causes severe disease in mice by establishing increased systemic viral loads. J. Virol. 82: 8411-8421.
21. Perry, S. T., M. D. Buck, E. M. Plummer, R. A. Penmasta, H. Batra, E. J. Stavale, K. L. Warfield, R. A. Dwek, T. D. Butters, D. S. Alonzi, et al. 2013. An iminosugar with potent inhibition of dengue virus infection in vivo. Antiviral Res. 98: 35-43.
22. Zellweger, R. M., R. Miller, W. E. Eddy, L. J. White, R. E. Johnston, and S. Shresta. 2013. Role of humoral versus cellular responses induced by a protective dengue vaccine candidate. PLoS Pathog. 9: e1003723.
23. Yauch, L. E., and S. Shresta. 2008. Mouse models of dengue virus infection and disease. Antiviral Res. 80: 87-93.
24. Zellweger, R. M., and S. Shresta. 2014. Mouse models to study dengue virus immunology and pathogenesis. Front. Immunol. 5: 151.
25. Petrovsky, N., and J. C. Aguilar. 2004. Vaccine adjuvants: current state and future trends. Immunol. Cell Biol. 82: 488-496.
26. Slifka, M. K., and I. Amanna. 2014. How advances in immunology provide insight into improving vaccine efficacy. Vaccine 32: 2948-2957.
27. Salek-Ardakani, S., R. Flynn, R. Arens, H. Yagita, G. L. Smith, J. Borst, S. P. Schoenberger, and M. Croft. 2011. The TNFR family members OX40 and CD27 link viral virulence to protective T cell vaccines in mice. J. Clin. Invest. 121: 296-307.
28. Mathew, A., and A. L. Rothman. 2008. Understanding the contribution of cellular immunity to dengue disease pathogenesis. Immunol. Rev. 225: 300-313.
29. Weiskopf, D., M. A. Angelo, E. L. de Azeredo, J. Sidney, J. A. Greenbaum, A. N. Fernando, A. Broadwater, R. V. Kolla, A. D. De Silva, A. M. de Silva, et al. 2013. Comprehensive analysis of dengue virus-specific responses supports an HLA-linked protective role for CD8+ T cells. Proc. Natl. Acad. Sci. USA 110: E2046-E2053.
30. Ng, J. K., S. L. Zhang, H. C. Tan, B. Yan, J. Maria Martinez Gomez, W. Y. Tan, J. H. Lam, G. K. Tan, E. E. Ooi, and S. Alonso. 2014. First experimental in vivo model of enhanced dengue disease severity through maternally acquired heterotypic dengue antibodies. PLoS Pathog. 10: e1004031.
31. Williams, K. L., S. Sukupolvi-Petty, M. Beltramello, S. Johnson, F. Sallusto, A. Lanzavecchia, M. S. Diamond, and E. Harris. 2013. Therapeutic efficacy of antibodies lacking Fcg receptor binding against lethal dengue virus infection is due to neutralizing potency and blocking of enhancing antibodies [corrected]. PLoS Pathog. 9: e1003157.
32. Johnson, A. J., and J. T. Roehrig. 1999. New mouse model for dengue virus vaccine testing. J. Virol. 73: 783-786.
33. Shresta, S., K. L. Sharar, D. M. Prigozhin, P. R. Beatty, and E. Harris. 2006. Murine model for dengue virus-induced lethal disease with increased vascular permeability. J. Virol. 80: 10208-10217.
34. Aguirre, S., A. M. Maestre, S. Pagni, J. R. Patel, T. Savage, D. Gutman, K. Maringer, D. Bernal-Rubio, R. S. Shabman, V. Simon, et al. 2012. DENV inhibits type I IFN production in infected cells by cleaving human STING. PLoS Pathog. 8: e1002934.
35. Ashour, J., J. Morrison, M. Laurent-Rolle, A. Belicha-Villanueva, C. R. Plumlee, D. Bernal-Rubio, K. L. Williams, E. Harris, A. Fernandez-Sesma, C. Schindler, and A. García-Sastre. 2010. Mouse STAT2 restricts early dengue virus replication. Cell Host Microbe 8: 410-421.
36. Yu, C. Y., T. H. Chang, J. J. Liang, R. L. Chiang, Y. L. Lee, C. L. Liao, and Y. L. Lin. 2012. Dengue virus targets the adaptor protein MITA to subvert host innate immunity. PLoS Pathog. 8: e1002780.
37. Morrison, J., M. Laurent-Rolle, A. M. Maestre, R. Rajsbaum, G. Pisanelli, V. Simon, L. C. Mulder, A. Fernandez-Sesma, and A. García-Sastre. 2013. Dengue virus co-opts UBR4 to degrade STAT2 and antagonize type I interferon signaling. PLoS Pathog. 9: e1003265.
38. Weiskopf, D., L. E. Yauch, M. A. Angelo, D. V. John, J. A. Greenbaum, J. Sidney, R. V. Kolla, A. D. De Silva, A. M. de Silva, H. Grey, et al. 2011. Insights into HLA-restricted T cell responses in a novel mouse model of dengue virus infection point toward new implications for vaccine design. J. Immunol. 187: 4268-4279.
39. Tan, G. K., J. K. Ng, S. L. Trasti, W. Schul, G. Yip, and S. Alonso. 2010. A non mouse-adapted dengue virus strain as a new model of severe dengue infection in AG129 mice. PLoS Negl. Trop. Dis. 4: e672.
40. Schul, W., W. Liu, H. Y. Xu, M. Flamand, and S. G. Vasudevan. 2007. A dengue fever viremia model in mice shows reduction in viral replication and suppression of the inflammatory response after treatment with antiviral drugs. J. Infect. Dis. 195: 665-674.
41. Dowd, K. A., and T. C. Pierson. 2011. Antibody-mediated neutralization of flaviviruses: a reductionist view. Virology 411: 306-315.
42. Pierson, T. C., D. H. Fremont, R. J. Kuhn, and M. S. Diamond. 2008. Structural insights into the mechanisms of antibody-mediated neutralization of flavivirus infection: implications for vaccine development. Cell Host Microbe 4: 229-238.
43. Appanna, R., S. Ponnampalavanar, L. Lum Chai See, and S. D. Sekaran. 2010. Susceptible and protective HLA class 1 alleles against dengue fever and dengue hemorrhagic fever patients in a Malaysian population. PLoS ONE 5: e13029.
44. Stephens, H. A., R. Klaythong, M. Sirikong, D. W. Vaughn, S. Green, S. Kalayanarooj, T. P. Endy, D. H. Libraty, A. Nisalak, B. L. Innis, et al. 2002. HLA-A and -B allele associations with secondary dengue virus infections correlate with disease severity and the infecting viral serotype in ethnic Thais. Tissue Antigens 60: 309-318.
45. Loke, H., D. B. Bethell, C. X. Phuong, M. Dung, J. Schneider, N. J. White, N. P. Day, J. Farrar, and A. V. Hill. 2001. Strong HLA class I-restricted T cell responses in dengue hemorrhagic fever: a double-edged sword? J. Infect. Dis. 184: 1369-1373.
46. Nguyen, T. P., M. Kikuchi, T. Q. Vu, Q. H. Do, T. T. Tran, D. T. Vo, M. T. Ha, V. T. Vo, T. P. Cao, V. D. Tran, et al. 2008. Protective and enhancing HLA alleles, HLA-DRB1∗0901 and HLA-A∗24, for severe forms of dengue virus infection, dengue hemorrhagic fever and dengue shock syndrome. PLoS Negl. Trop. Dis. 2: e304.
47. Chau, T. N., N. T. Hieu, K. L. Anders, M. Wolbers, B. Lien, L. T. Hieu, T. T. Hien, N. T. Hung, J. Farrar, S. Whitehead, and C. P. Simmons. 2009. Dengue virus infections and maternal antibody decay in a prospective birth cohort study of Vietnamese infants. J. Infect. Dis. 200: 1893-1900.
48. Chau, T. N., N. T. Quyen, T. T. Thuy, N. M. Tuan, D. M. Hoang, N. T. Dung, B. Lien, N. T. Quy, N. T. Hieu, L. T. Hieu, et al. 2008. Dengue in Vietnamese infants: results of infection-enhancement assays correlate with age-related disease epidemiology, and cellular immune responses correlate with disease severity. J. Infect. Dis. 198: 516-524.
49. Halstead, S. B., J. E. Scanlon, P. Umpaivit, and S. Udomsakdi. 1969. Dengue and chikungunya virus infection in man in Thailand, 1962-1964. IV. Epidemiologic studies in the Bangkok metropolitan area. Am. J. Trop. Med. Hyg. 18: 997-1021.
50. Kliks, S. C., S. Nimmanitya, A. Nisalak, and D. S. Burke. 1988. Evidence that maternal dengue antibodies are important in the development of dengue hemorrhagic fever in infants. Am. J. Trop. Med. Hyg. 38: 411-419.
51. Simmons, C. P., T. N. Chau, T. T. Thuy, N. M. Tuan, D. M. Hoang, N. T. Thien, B. Lien, N. T. Quy, N. T. Hieu, T. T. Hien, et al. 2007. Maternal antibody and viral factors in the pathogenesis of dengue virus in infants. J. Infect. Dis. 196: 416-424.
52. PrabhuDas, M., B. Adkins, H. Gans, C. King, O. Levy, O. Ramilo, and C. A. Siegrist. 2011. Challenges in infant immunity: implications for responses to infection and vaccines. Nat. Immunol. 12: 189-194.